Robert A. Ingram
December 6, 1942 - March 24, 2023
Mr. Robert Ingram, also known as Bob, was a General Partner at Hatteras from 2007 until his passing in March, 2023. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of GlaxoWellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram was Chairman of the Boards of BioCryst Pharmaceuticals, Inc. and Black Diamond Therapeutics, Inc. He recently retired as Chairman of the Board of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, and as Chairman of the Board of Cree. Mr. Ingram also served on the board of directors of HBM Healthcare Investments, Ltd., a Switzerland-based venture capital company. In 2013, Bob received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.
At the request of US President George H.W. Bush, Bob formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. He accepted his third Presidential appointment most recently in 2019, when he was appointed by President Donald J. Trump’s administration to serve on the Presidential Cancer Panel. In 2014, Bob received the North Carolina Award for public service, the highest civilian honor the state can bestow on an individual. Bob served on the boards of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the Board of the North Carolina GlaxoSmithKline Foundation.
Bob was a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation.
Bob graduated from Eastern Illinois University with a BS degree in Business Administration.
COMMUNITY AND BOARD ENGAGEMENTS:
Bob was a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation.